MRK
Merck & Co Inc$123.82 ▲
+3.79% (+4.52)
Price Chart — 6 Months
Technical Indicators
RSI (14) Neutral
64.99
30 70
MACD Bearish
MACD 3.314
Signal 3.538
Histogram -0.225
Bollinger Bands
Upper 126.72
Middle 119.75
Lower 112.78
Day Summary
Open $119.68
High $124.00
Low $119.68
Prev Close $119.30
Company News
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Merck Reshapes Drug Business As Keytruda Era Nears Turning Point
These Stocks Lead Dow Jones In February. Hint: It's Not AI Companies.
Merck Stock, Up 18% In 2026, Ticks Another Box. Is It Now A Buy?
Sector Update: Health Care Stocks Advance Late Afternoon
Sunrun stock nosedives on outlook, Merck job cuts, Jefferies sinks
What's going on in today's session: S&P500 movers
Sector Update: Health Care Stocks Higher Friday Afternoon